SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin’s subsidiary receives USFDA approval for Generic LYRICA capsules

05 Jul 2012 Evaluate

Lupin’s subsidiary - Lupin Pharmaceuticals Inc. (collectively Lupin) has received final approval for its Pergabalin capsules, 0.25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg from United States Food Drugs Administration (FDA) to market a generic version of CP Pharmaceuticals C.V.LYRICA (Pregabalin) capsules.

Lupin's Pergabalin capsules 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg are the AB-rated generic equivalent of LYRICA capsules, which is indicated for neuropathic pain associated with diabetic peripheral neuropathy, post herpetic neuralgia, adjunctive therapy for Adult patients with partial onset seizures and fibromyalgia. LYRICA capsules had annual US sales of approximately $1.8 billion for the twelve months ending March 2012, as per IMS Health sales data.

Lupin has a vibrant presence in the Indian pharmaceuticals market and has over the past several years made major strides in expanding its therapy portfolio. The company has a robust promotion and distribution setup along with a strong presence in various therapeutic areas, including the fast growing diabetes market.

Lupin Share Price

2496.05 -6.85 (-0.27%)
10-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1935.25
Dr. Reddys Labs. 1245.50
Cipla 1438.75
Zydus Lifesciences 1150.50
Lupin 2496.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: